A Randomized, Parallel Group, Placebo-controlled, Multicenter Phase 3 Study With a PK Sub-group Study With Beclomethasone HFA at 400 μg and 800 μg Daily Doses Compared to Placebo and QVAR in Persistent Asthma.
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 18 Jul 2019
Price : $35 *
At a glance
- Drugs Beclometasone (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Adamis Pharmaceuticals Corporation
- 15 Jul 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 15 Mar 2019 According to an Adamis Pharmaceuticals Corporation media release, the company expects to initiate the enrollment in this study in 2019.
- 06 Feb 2019 Status changed from planning to not yet recruiting.